Month: 2025-09

DUBAI, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - 31 CONCEPT (31C), a leading UAE-based cybersecurity innovator, today announced the strategic acquisition of Xynthor AI Software Inc., a Canadian company pioneering AI-native Data Loss Prevention (DLP) solutions. This acquisition strengthens 31C's commitment to advancing Deep Packet Intelligence (DPI), corporate security, and data sovereignty in an AI-centric world.31 Concept & XynthorBy integrating Xynthor's "DLP for AI Era" with 31C's DPI expertise, the combined platform will deliver the most comprehensive AI-aware security solution available. This move addresses the growing need for security systems capable of handling modern AI-driven workflows.Why It MattersThe rise of generative AI tools such as ChatGPT and Claude has outpaced the capabilities of traditional DLP systems, which were built for structured data and static rules. High-profile incidents, including the accidental leakage of proprietary source code by Samsung engineers using ChatGPT, highlight the urgent need for AI-specific safeguards.Misha Hanin, CEO of 31C, emphasized: "The convergence of AI and cybersecurity is the most significant paradigm shift our industry has ever seen. Traditional methods cannot manage the dynamic, context-aware data flows of today's AI environments. Through this acquisition, we are pioneering an entirely new category of AI-native security solutions."Xynthor's Breakthrough TechnologyXynthor brings several unique differentiators:AI Data Guardian: Prevents sensitive information from leaving the organization using NLP-driven detection.Air-Gapped Architecture: Keeps analysis inside the client's environment, ensuring privacy and compliance.Context-Aware Intelligence: Reduces false positives through AI-driven classification and behavioral analysis.Private LLM Protection: Enables safe use of internal large language models without external exposure.Seamless Integration: Works with existing infrastructure while supporting regulations like HIPAA and GDPR.Comprehensive AI-Era PlatformThe integrated platform enhances DPI with real-time policy management, adaptive threat detection, and behavioral analytics. It also streamlines compliance with GDPR, HIPAA, PCI DSS, and upcoming AI governance standards.Boris Heismann, CTO of 31C, stated: "We're not only responding to current demands but anticipating tomorrow's challenges. Combining DPI with AI-native DLP creates a future-ready security platform."Strategic ImpactThe global cost of data breaches averages over $4 million per incident, and AI-driven risks are only increasing. By uniting DPI and AI-native DLP, 31C positions itself as a global leader capable of addressing these critical challenges.This acquisition aligns with 31C's growth strategy, including performance-based incentives tied to Xynthor's product success. Both companies will continue to operate from the UAE and Canada, combining their strengths to accelerate innovation and market expansion.About 31CFounded in the UAE, 31C is a cybersecurity company specializing in Deep Packet Intelligence, corporate security, and data sovereignty. Its innovative approach makes it a trusted partner for enterprises, governments, and regulators worldwide.About Xynthor AIBased in Canada, Xynthor AI develops AI-native security platforms designed to protect organizations using generative AI, ensuring both safety and compliance in the AI era.For more information about 31C's Next Gen DPI solutions, visit https://31c.io.Contact InformationMisha HaninCEOmisha.hanin@31c.ioSOURCE: 31 Concept Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

迪拜，阿聯酋, 2025年9月29日 - (亞太商訊 via SeaPRwire.com) - 阿聯酋領先的網路安全創新企業 31 CONCEPT (31C) 今日宣布，已策略性收購加拿大公司 Xynthor AI Software Inc.，該公司在 AI 原生資料外洩防護（Data Loss Prevention, DLP）解決方案領域具開創性。此次收購將進一步鞏固 31C 致力推動深度封包智慧（Deep Packet Intelligence, DPI）、企業安全，以及在 AI 為核心的世界中維護資料主權的承諾。31 Concept 與 Xynthor透過整合 Xynthor 的「AI 時代 DLP」與 31C 在 DPI 領域的專業，雙方的結合平台將提供市場上最完整的 AI 感知型安全解決方案。此舉正面回應了現代 AI 驅動工作流程 對能夠應對的新一代安全系統日益增長的需求。為什麼這很重要生成式 AI 工具（如 ChatGPT 與 Claude）的崛起，已遠遠超越傳統 DLP 系統的能力，而這些系統僅針對結構化資料與靜態規則而設計。高知名度的事件——例如 三星工程師在使用 ChatGPT 時意外洩露專有原始碼——凸顯了建立 專為 AI 設計的安全防護 的迫切性。31C 執行長 Misha Hanin 強調：「AI 與網路安全的匯聚，是我們產業史上最重大的典範轉移。傳統方法無法處理今日 AI 環境中動態、具語境感知的資料流。透過此次收購，我們正在開創一個全新的 AI 原生安全解決方案 類別。」Xynthor 的突破性技術Xynthor 帶來幾項獨特的差異化：AI 資料守護者：透過 NLP 驅動的偵測，防止敏感資訊離開組織。隔離式架構：將分析保持在客戶環境內，確保隱私與合規性。情境感知智慧：透過 AI 驅動的分類與行為分析，減少誤判。私有 LLM 保護：讓內部大型語言模型能安全使用，而不會暴露於外部。無縫整合：可與既有基礎設施配合運作，同時支援 HIPAA 和 GDPR 等法規。全面性的 AI 時代平台整合的平台透過即時政策管理、自適應威脅偵測與行為分析，強化 DPI。它同時簡化了符合 GDPR、HIPAA、PCI DSS 以及即將推出的 AI 治理標準的流程。31C 技術長 Boris Heismann 表示：「我們不僅在回應當前的需求，也在預見未來的挑戰。將 DPI 與 AI 原生 DLP 結合，創造出一個為未來做好準備的安全平台。」策略影響全球資料外洩的平均成本每次超過 400 萬美元，而 AI 驅動的風險只會持續增加。透過結合 DPI 與 AI 原生 DLP，31C 定位自己為能解決這些關鍵挑戰的全球領導者。此次收購符合 31C 的成長策略，其中包括與 Xynthor 產品成功掛鉤的績效獎勵。兩家公司將繼續在阿聯酋與加拿大營運，結合雙方優勢，加速創新與市場拓展。關於 31C31C 成立於阿聯酋，是一家專注於深度封包智慧（DPI）、企業安全與資料主權的網路安全公司。其創新的方法使其成為全球企業、政府及監管機構信賴的合作夥伴。關於 Xynthor AIXynthor AI 總部位於加拿大，開發 AI 原生安全平台，旨在保護使用生成式 AI 的組織，確保在 AI 時代的安全與合規。欲了解更多有關 31C 次世代 DPI 解決方案的資訊，請造訪 https://31c.io 。聯絡資訊Misha HaninCEOmisha.hanin@31c.io來源: 31 Concept Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 29, 2025 - 28 September, The world's first 9,300 CEU methanol dual-fuel Pure Car and Truck Carrier (PCTC), "CM HONG KONG", celebrated its maiden voyage with a ceremony in Tsing Yi, Hong Kong. Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, Deputy Director of the Liaison Office of the Central People's Government in the HKSAR, Qi Bin, and Chairman of China Merchants Group Limited, Miao Jianmin, etc. attended the ceremony, with Executive Vice President of China Merchants Group Limited, Deng Renjie, as the master of ceremonies.During the event, a commemorative plaque was presented to the ship's captain. Guests toured the vessel's bridge, crew quarters, and innovative methanol dual-fuel system, witnessing its advancements in low-carbon technology and operational efficiency.Built for China Merchants Energy Shipping (CMES), "CM HONG KONG" is the first large-scale car carrier powered by a methanol dual-fuel system, enabling seamless switching between conventional fuel and methanol. Compliant with IMO Tier III emission standards, it achieves over 70% emissions reduction when using green methanol. The ship, measuring 219.9 meters long and 37.7 meters wide, has a design capacity of 9,300 CEUs, with an actual capacity of up to 9,492 CEUs. Its 78,416-square-meter loading area, equivalent to 11 football fields, features 13 decks, including three adjustable lift decks and three tailored for hydrogen fuel cell vehicles. Dual stern and side ramps boost loading/unloading efficiency by 30%. Safety is enhanced with 156 CCTV cameras and thermal imaging infrared sensors across all decks."CM HONG KONG" embarked on its inaugural China-to-Europe route, unloading vehicles in Hong Kong before heading to Europe. Leveraging Hong Kong's free port status, CMES aims to advance the "green fuel trade + port services" model, fostering economic growth, attracting international vessels for green fuel bunkering, and strengthening Hong Kong's role as a global green maritime hub.Vice-chairperson of the National Committee of the Chinese People's Political Consultative Conference, Leung Chun-ying, delivered a speech at the ceremony.Chief Secretary for Administration of the HKSAR, Chan Kwok-kei, delivered a speech at the ceremony.Chairman of China Merchants Group Limited, Miao Jianmin, delivered a speech at the ceremony. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年9月29日 - (亞太商訊 via SeaPRwire.com) - 9月28日，全球首艘9300CEU（標準車位）甲醇雙燃料動力滾裝船"CM HONG KONG"輪（中文名"港榮"輪）首航香港儀式在香港青衣舉行。全國政協副主席梁振英、香港特區政府政務司司長陳國基、中央政府駐港聯絡辦副主任祁斌、招商局集團董事長繆建民等出席，招商局集團副總經理鄧仁傑主持。梁振英在致辭時表示，"CM HONG KONG"輪是高新科技與香港航運發展的深度融合，標誌香港國際航運中心地位的提升，寄託了對香港繁榮穩定的美好願景。招商局集團作為香港歷史悠久的中資企業，始終與國家發展大局同頻共振，推動香港經濟社會繁榮發展。希望招商局集團持續創新，為香港和國家長遠發展貢獻力量。陳國基表示，招商局集團一直積極配合特區政府政策，走在綠色轉型的前線。"港榮"輪使用可以減少七成以上溫室氣體排放的綠色燃料，充分體現科技創新和環保理念的深度融合。期盼招商局集團繼續深耕香港、貢獻香港發展，在建設國際金融、航運、貿易三中心，以及國際高端人才集聚高地方面，發揮更大作用。繆建民表示，招商局集團與香港共榮共生，積極助力香港航運業高品質發展。"CM HONG KONG"輪冠以香港之名，承載繁榮祝願，更是招商局集團紮根香港的生動注腳。未來，招商局集團將加快綠色船舶建設，持續提升世界航商大會平台影響力，推動港航物流綠色化，助力香港打造全球航運業綠色低碳發展新樣本。儀式上，香港海事處處長王世發向"CM HONG KONG"輪船長頒發紀念牌。嘉賓們隨後登船參觀駕駛台、生活區及甲醇雙燃料動力系統，體驗該輪在低碳技術與裝載效率上的突破。有關機構嘉賓、招商局集團有關部門和二級公司負責人參加活動。"CM HONG KONG"輪由招商輪船訂造，是全球首艘採用甲醇雙燃料動力系統的大型汽車滾裝船。動力系統支援燃油與甲醇靈活切換，滿足國際海事組織Tier Ⅲ排放標準，使用綠色甲醇時可減排超70%。該船總長219.9米，型寬37.7米，設計裝載容量9300個標準車位元，實際可達9492個。總裝車面積78416平方米，約相當於11個標準足球場。配備13層裝載甲板，其中3層為可調節升降甲板，另有3層專為氫燃料電池車設計。尾跳與側跳雙裝卸通道提升裝卸效率30%。全船配備156個閉路電視監控系統，13層甲板均設耦合熱成像紅外探頭，確保安全。"CM HONG KONG"輪首航執行中國至歐洲航線，在香港卸車後將駛往歐洲。招商輪船將充分利用香港自由港的獨特優勢，參與推動香港"綠色燃料貿易+港口服務"模式，助力打造新的經濟增長點，吸引更多國際船舶來港加注綠色燃料，為香港綠色航運樞紐的發展注入新動能。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - The future arrived today in Singapore as the World Quantum Summit 2025 (WQS) — themed “Quantum Unboxed: Extending the Reach of AI” — concluded at the Sheraton Towers Singapore with a full house attendance filling the ballroom to capacity. The overwhelming turnoutunderscored the growing global appetite for practical quantum solutions that extend the power of artificial intelligence and accelerate its real-world impact.This year’s summit was not a standalone event but the culmination of a three-day intensive journey into the future of computing and intelligence. On 23–24 September, participants took part in a sold-out Executive Workshop on Quantum and AI, which built foundational understanding of quantum principles, emerging architectures, and integration strategies. The final day brought it all together, showcasing how those concepts are now being deployed in industry — from real-world applications to large-scale investment strategies.Unlike traditional conferences focused solely on research or theory, WQS 2025 brought together the entire ecosystem driving quantum innovation forward. The summit featured practitioners representing different quantum approaches, policy makers, venture investors, academics, corporates, researchers, and ecosystem partners — all converging under one roof to chart the path from lab breakthroughs to industry-scale adoption. On the exhibition floor, leading players such as ST Engineering, QBoson, and TM Research & Development showcased quantum - enhanced solutions in optimisation, secure computing, and AI acceleration. Meanwhile, Gold Capital Network Partners — IMGT and IWC Management — hosted curated sessions connecting founders and investors to accelerate funding into quantum ventures poised for growth.A key highlight was the line-up of 19 world-class speakers, each offering cutting-edge insights into how quantum is transforming the AI landscape. Among them were Assoc. Prof. Mile Gu, Deputy Director of the Nanyang Quantum Hub at Nanyang Technological University; Jeremy Woo, Senior Technical Advisor at D-Wave System; Deepak Waghmare, CTO (APJC) of Dell Technologies; Ujjwal Kumar, Principal Architect, Office of the CTO at Microsoft Asia; Dr. Simon See, Senior Director and Global Head of the NVIDIA AI Technology Center; Bruno Aznar Martinez, R&D Software Developer at Keysight Technologies; Raghunath Koduvayur, CEO of RAQS Quantum; Gao Qi, Algorithm Director at QBoson; Ken Chew, CEO and Partner of IWC Management; and Tony Gu, General Partner at NGC Ventures. They were joined by Ong Yongcheng of Insignia Ventures, Dr. Amelia Tan of ST Engineering, Eric Lee of Deloitte Southeast Asia, Atsushi Sugiura of Oxford Quantum Circuits, Hidetoshi Matsumura of Fujitsu Limited, Ray Han of SAP, Duleesha Kulasooriya of Deloitte, Manisha Sharma Kohli of Google, and Simon Lawrie of AWS.Throughout the summit, a clear narrative emerged: quantum computing has moved beyond theory into strategic deployment, offering a powerful multiplier for AI. Industry leaders showcased case studies where quantum-enhanced AI is already delivering breakthrough results — from accelerating molecular simulations and optimising financial portfolios to solving supply chainchallenges previously considered intractable. Discussions highlighted how enterprises are integrating quantum capabilities directly into their AI workflows, achieving dramatic improvements in processing power, speed, efficiency, and cost-to-insight.The summit also reflected the shifting investment landscape. As quantum technologies mature, institutional and venture capital investors are moving rapidly to back companies with commercially viable products and near-term revenue potential. “Quantum is no longer the future — it’s today’s most powerful strategic edge and already seeing some real applications,” said Ken Chew, CEO of IWC Management. “The confluence of quantum and AI and their cross-synergies are powerful and those who integrate it into their AI stack early will potentially define the competitive landscape of the next decade.”By the close of the event, one message was clear: quantum will not replace AI — it will supercharge it. With practitioners, investors, policymakers, and researchers now aligned on the urgency of adoption, the era of practical quantum applications is no longer a distant vision — it is here, and it is redefining howindustries think about computation, intelligence, and innovation.The World Quantum Summit has firmly established itself as Asia’s premier platform for quantum commercialisation, bridging science, industry, and capital to accelerate real-world adoption. With its unique focus on applications over abstraction and its ability to convene the full quantum ecosystem, WQS is not just a conference — it is a catalyst for the next wave of technological transformation.Media Contact:Eric KhooConference Director, TPGI Pte Ltderic.khoo@pinnaclegroup.global+65 8383 2480 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hong Kong Department of Health accepts NDA for dorzagliatin, the world’s first approved glucokinase activator (GKA).Builds on China approval and strong Phase III and real-world clinical results showing durable glucose control and safety.Positions Hong Kong as a strategic gateway for Hua Medicine’s global expansion into Southeast Asia and beyond.SHANGHAI, Sept 29, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (“the Company”, HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world’s first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D).The acceptance of the NDA marks an important milestone in Hua Medicine’s strategy to expand beyond China, bringing its innovative, disease-modifying treatment to more patients across Asia and ultimately to global markets.With more than half a million people living with diabetes in Hong Kong and nearly 240 million across Asia, the NDA represents a significant step toward addressing one of the region’s most urgent health challenges.A first-in-class therapy with global potentialDorzagliatin was approved for marketing by the China National Medical Products Administration (NMPA) in September 2022 for two indications, both to improve blood glucose control for T2D patients, 1) It can be used as mono-treatment for drug-naïve T2D patients, as first-line treatment, 2) When metformin hydrochloride alone has poor blood glucose control, it can be used in combination with metformin hydrochloride. Unlike conventional drugs that manage symptoms, dorzagliatin targets the root cause of blood sugar dysregulation by repairing the function of glucokinase (GK), the body’s glucose sensor. By restoring glucose sensitivity, dorzagliatin helps maintain blood sugar balance and supports long-term disease management.Results from two Phase III registration trials in China demonstrated that dorzagliatin significantly and sustainably lowered HbA1c levels, improved pancreatic β-cell function, and reduced insulin resistance, all while showing strong safety and tolerability. Findings are being further validated in ongoing real-world studies, of which some interim analysis and data were presented at the 2025 American Diabetes Association (ADA) Scientific Sessions.Strategic gateway to new marketsHong Kong has established a comprehensive, community-based system for diabetes management and serves as a medical and financial hub for the region. Research findings from the Hong Kong Diabetes and Obesity Research Institute at The Chinese University of Hong Kong indicate that the implementation of a community-based public-private collaboration model for diabetes management provided significant benefits to the community. The advanced experience in Hong Kong is of great significance for improving the quality of life of diabetes patients, controlling the progression of the disease, and reducing the burden on the healthcare system. Once approved in Hong Kong, it will also provide clinical application of dorzagliation for the personalized management of diabetes.According to Hong Kong's former new drug approval mechanism, applicants were required to submit to the authority new drug registration certificates issued by the drug regulatory agencies of two or more recognized countries, as well as other specified relevant documents, in order to support the approval and marketing of the product. Under the newly established "1+" mechanism, after meeting requirements such as local clinical data support and having the applicable scope of the new drug endorsed by local experts, an applicant only needs to submit the approval from one (instead of the original two) reference drug regulatory authority to apply for registration of the new drug in Hong Kong. This mechanism initially applied to new drugs for the treatment of serious or rare diseases, and has been extended to all new drugs since 2024.Under the leadership of Ms. Beili Cao, Vice President of Department of Corporate Operation and Great Bay Development, Hua Medicine has conducted sufficient and in-depth communications with local clinical experts and regulatory authorities in Hong Kong, and became an early pioneer of this mechanism. The Company filed its application for registration of dorzagliatin in Hong Kong at the end of July, and the application was officially accepted by the end of September.Dr. Li Chen, Founder and Chief Executive Officer of Hua Medicine, said: “Acceptance of dorzagliatin’s NDA in Hong Kong is not only recognition of its clinical value but also a pivotal step in Hua Medicine’s international journey. Hong Kong’s unique position as a regional healthcare leader and financial hub makes it the ideal gateway for expanding dorzagliatin’s reach into Southeast Asia and beyond. We are committed to working with local doctors and partners in Hong Kong to explore dorzagliatin’s potential in both treatment and prevention of prediabetes and early-stage diabetes, ensuring more patients worldwide can benefit from this breakthrough therapy.”Dorzagliatin: A transformative T2D treatmentDorzagliatin was approved in September 2022 in China, and it was included in the country’s National Reimbursement Drug List (NRDL) as of January 1, 2024.Dorzagliatin can be used alone as a first-line therapy for newly diagnosed patients, or together with metformin when blood sugar control is inadequate. Unlike many other approved oral antidiabetes drugs, no dose adjustment is required for patients with kidney impairment. It works by repairing the body’s glucose sensor, glucokinase (GK), restoring glucose sensitivity and long-term blood sugar balance. It acts across key organs—stimulating insulin secretion in the pancreas, boosting GLP-1 secretion in the gut, and regulating glycogen in the liver. This multi-target approach addresses the root cause of Type 2 diabetes, not just its symptoms.The NDA application in Hong Kong is based on the results of two Phase III registration clinical studies conducted in China evaluating the use of dorzagliatin monotherapy and in combination with metformin for the treatment of patients with Type 2 diabetes. Two studies have shown that for two categories of T2D patients—those newly diagnosed and not yet on medication, and those who have failed to respond adequately to metformin therapy— dorzagliatin can sustainably and effectively lower patients' HbA1c levels by repairing defects in the glucose sensor function of GK, significantly reduce postprandial two-hour blood glucose levels (2h-PPG), achieve high glycemic control rates without hypoglycemia, demonstrate good safety and tolerability, and continuously improve β-cell function and reduce insulin resistance.Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsWebsite: ir@huamedicine.comMediaWebsite: pr@huamedicine.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港衛生署受理多格列艾汀的新藥上市許可申請（NDA），多格列艾汀是全球首個獲批的葡萄糖激酶激活劑（GKA）基于中國大陸的上市批准，以及强大的III期臨床研究和真實世界臨床結果，多格列艾汀顯示出持久的血糖控制和安全性香港將成爲華領醫藥向東南亞及全球拓展的重要支點上海，2025年9月29日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（"公司"，香港聯交所股份代號：2552）宣佈，中國香港特別行政區衛生署已正式受理多格列艾汀（dorzagliatin）的新藥上市許可申請（NDA）。多格列艾汀是世界上第一個獲批准用于治療2型糖尿病（T2D）的葡萄糖激酶激活劑（GKA）。此次NDA被受理是華領醫藥拓展中國大陸以外市場戰略的一個重要里程碑，有望將其創新的疾病療法帶給更多亞洲患者，幷最終推向全球市場。香港有超過50萬人患有糖尿病，亞洲有近2.4億人患有糖尿病，多格列艾汀的NDA是解决該地區最緊迫的健康挑戰之一的重要一步。一款具有全球潜力的首創療法多格列艾汀于2022年9月獲得中國國家藥品監督管理局（NMPA）的上市批准，獲批兩個適應症：1）單獨用藥治療未經藥物治療的2型糖尿病患者，可以用于一綫治療；2）在單獨使用鹽酸二甲雙胍血糖控制不佳時，與鹽酸二甲雙胍聯合使用，改善成人2型糖尿病患者的血糖控制。與傳統的降糖藥物不同，多格列艾汀通過修復人體的葡萄糖傳感器--葡萄糖激酶（GK）的功能，直擊血糖調節异常的根源。通過恢復葡萄糖敏感性，多格列艾汀有助于維持血糖平衡，幷支持疾病的長期管理。在中國開展的兩項III期注册臨床研究結果顯示，多格列艾汀能顯著且持續地降低糖化血紅蛋白（HbA1c）水平，改善胰島β細胞功能，降低胰島素抵抗，同時具有良好的安全性和耐受性。目前正在進行的真實世界研究進一步驗證了這些發現，其中部分中期分析結果和數據已在2025年美國糖尿病協會（ADA）科學年會上公佈。通往新市場的戰略門戶作爲地區的醫療和金融樞紐，香港地區在糖尿病社區管理中已形成了一套較爲完善且行之有效的體系。香港中文大學香港糖尿病及肥胖症研究所的研究成果顯示，推行社區爲本的公私營協作糖尿管理模式成效顯著。香港地區的先進經驗對提升糖尿病患者生活質量、控制病情發展及减輕醫療負擔具有重要意義，待多格列艾汀在香港獲批，也將爲産品的糖尿病個性化管理提供更豐富的臨床應用經驗。香港過去的新藥審批制度規定，申請人須向管理局提供由兩個或以上認可國家的藥物監管機關發出的新藥注册證明文件，以及其他規定的相關文件，才能支持該産品的審批上市。但在新設的"1+"機制下，在符合本地臨床數據支持等要求，幷經本地專家認可新藥的適用範圍後，只須提交一個（而非原來的兩個）參考藥物監管機構的許可，便可以在香港申請注册。該制度最早適用于治療嚴重或罕見疾病的新藥，2024年開始擴展至所有新藥。在集團運營和大灣區發展部副總裁曹蓓莉女士的領導下，華領醫藥積極與香港當地臨床專家和監管部門進行了充分且深入的溝通，成爲這一政策的早期探路者。華領醫藥在7月底順利完成多格列艾汀的新藥遞交申請，幷于9月底正式受理。華領醫藥創始人兼CEO陳力博士表示："多格列艾汀在香港的NDA獲得受理，不僅是對多格列艾汀臨床價值的認可，也是華領醫藥國際化進程中的重要一步。香港是地區醫療領域的引領者和金融樞紐，其獨特的地位使其成爲將多格列艾汀的影響力拓展至東南亞及其他地區的理想門戶。我們會繼續與香港本地醫生及合作夥伴携手探索多格列艾汀在糖尿病前期、糖尿病早期治療和預防等方面的潜力，讓全球更多患者能從這一突破性療法中獲益。"多格列艾汀：一款變革性的2型糖尿病治療藥物多格列艾汀于2022年9月在中國大陸獲批，幷被納入2024年1月1日正式執行的國家醫保藥品目錄。多格列艾汀可作爲新診斷患者的一綫單藥治療藥物，也可在二甲雙胍單獨用藥血糖控制不佳時與二甲雙胍聯合使用，用于治療成人2型糖尿病。與許多其它已獲批的口服抗糖尿病藥物不同，腎功能不全患者使用該藥物無需調整劑量。其作用機制是修復人體的葡萄糖傳感器--葡萄糖激酶，恢復葡萄糖敏感性和長期血糖平衡。多格列艾汀可以作用于多個關鍵器官：刺激胰腺分泌胰島素、促進腸道分泌GLP-1、調節肝臟中的糖原。這種多靶點的作用方式可以直擊2型糖尿病的根源，而非僅僅緩解其症狀。此次在香港地區的NDA申請基于兩項在中國開展的多格列艾汀單藥以及聯合二甲雙胍治療 T2D 患者的 III 期注册臨床研究結果。兩項研究表明，針對新診斷未用藥和二甲雙胍足量治療失效的兩類2型糖尿病患者，通過修復GK的傳感器功能缺陷，多格列艾汀能够持續、有效降低患者的HbA1c水平，顯著降低餐後兩小時血糖值（PPG），在無低血糖條件下血糖達標率高，具有良好的安全性和耐受性，幷且能够持續改善β細胞功能和降低胰島素抵抗。前瞻性聲明本文包含有關華領醫藥以及産品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，于作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情况，我們幷無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文幷理解，由于各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差异。關于華領華領醫藥（"本公司"）是一家總部位于中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注于未被滿足的醫療需求，爲全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依托全球優勢資源，研究開發突破性的技術和産品，引領全球糖尿病醫療創新。公司核心産品華堂寧®（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶爲靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧®已獲得中國國家藥品監督管理局（NMPA）的上市批准，用于單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對于腎功能不全患者，無需調整劑量，是一款可用于腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Sep 29, 2025 - (ACN Newswire via SeaPRwire.com) – Quantum Solutions Co., Ltd. (Tokyo Stock Exchange Code: 2338.T, “Quantum”) announced its strategic financing initiative on September 26 to issue 44 million shares to a blue-chip investor mix of three heavyweight institutions, providing the necessary permanent capital and network access to position Quantum as a potential frontrunner in the world of Ethereum (ETH) listed strategies and a showcase standout in the Tokyo stock market.For Japanese investors, this represents another significant commitment by leading US capital, following Warren Buffett’s investment in Japan’s five major trading companies. For international investors, it signals that Tokyo’s stock market is an increasingly attractive destination for global capital, welcoming new opportunities for “smart money”.Dream Team of Global Capital Aligns for Quantum, International Demand for Japanese Equities Continues to GrowQuantum’s investor line-up is a market stunner in the emerging field of crypto-linked equities. Susquehanna International Group (SIG), investing via CVI Investments, holds the capital firepower to accelerate Quantum’s ETH accumulation and expand its balance sheet for upcoming fundraising rounds. With a portfolio that includes early investments in ByteDance and Strategy Inc. (NASDAQ: MSTR), SIG is a Tokyo Stock Exchange participant, offering the robust capital infrastructure that analysts consider essential for a successful Digital Asset Treasury (DAT).Cathie Wood affirms her position as the world’s leading investor in crypto-linked equities with ARK Invest’s first direct foray into APAC-listed opportunities. In the US market, ARK has a track record for identifying category leaders such as ETH Treasury Bitmine Immersion Technologies (NYSE: BMNR) and cryptocurrency exchange Coinbase (NASDAQ: COIN). By adding Quantum, Wood extends her expertise to the Tokyo market, bringing visibility to Quantum in front of the global investing audience as the region’s most promising ETH Treasury initiative.The third participant is Hong Kong-based Integrated Asset Management (IAM), led by Mr. TC Yam. As the majority shareholder of Forbes Media, IAM’s cross-sector presence in international finance and media resources bolsters Quantum’s capital depth and reputational standing. Like ARK, IAM makes its first public investment in the Tokyo stock market, signaling growing confidence among global institutional investors in Japan's equity market.The fundraise utilizes convertible bonds and both floating and fixed strike price warrants for a total issuance of approximately 44 million shares, nearly doubling the company’s existing share capital. None of the instruments are priced at a discount, a rarity for DAT fundraises, suggesting that the incoming investors are targeting long-term growth prospects. As of market closing on September 26, the nominal value of the financing round comes to over JPY 26 billion (approx. USD 180 million), with the first tranche valued at JPY 22.1 billion (approx. USD 150 million).First ETH Treasury in Japan — A Differentiated Strategy Offering Long-Term Returns on EquityAccording to research reports by leading investment banks, the key determinants of success for listed Digital Asset strategies are robust access to capital and a team with operational blockchain expertise. Through this fundraising initiative, Quantum taps into fresh sources of capital and aligns with investors of strong reputation, prompting market expectations of long-term backing.Quantum CEO Francis B. Zhou is no newcomer to the Digital Asset industry, as one of the first institutional investors and operators in the blockchain space. In 2018, Zhou acquired the world’s second largest ETH mining facility, based in Jokkmokk, Sweden. Zhou maintains investments in early stage blockchain projects alongside film and IP holdings in his venture investment portfolio, and brings a network of experienced blockchain operators, including Head of Crypto Strategy Donny Chi.Proceeds from Quantum’s financing initiative will be used to accumulate ETH. Although BTC has demonstrated adoption as a store-of-value, ETH is the foundational asset for blockchain applications, enabling companies like Quantum to explore attractive yield-generating opportunities to drive a blend of organic and inorganic growth for the company’s core treasury and balance sheet.The appeal of yield-bearing strategies is supported by data from the US market, which indicates that listed ETH Treasuries trade at a price-to-book multiple of 7.72x, more than 3 times higher than that of listed BTC Treasuries. More remarkably, the price-to-book of ETH Treasuries is trending upwards, increasing by over 20% within the trading month of September, demonstrating that the market expectations continue to strengthen for listed ETH Treasuries as it relates to long-term returns on equity.Zhou and the Quantum Solutions team have a history of exploring growth frontiers, consequently developing industry traction in AI computing, GPU hosting, and IP gaming. This positions the company to pursue unique opportunities beyond overcrowded sectors in Real World Asset (RWA) space to potentially generate more attractive returns.With the fundraise, Quantum’s notional price-to-book multiple is estimated to be less than 30% of the market median. Assuming that the company can reach its fair value, the structure of the fundraise allows the company to rapidly accelerate its capital accumulation to reach the target of 100,000 ETH within the near term, positioning Quantum among the leading ETH Treasury companies globally.Growth Driven Policies in Japan Encourage Prospects for Long-Term Shareholder ValueConsistent government support for the blockchain industry and increasing clarity in regulations are ushering in a more investor-friendly market for Digital Assets in Japan. Whereas the US market already has ETH Treasury companies such as Bitmine (NASDAQ: BMNR) and SharpLink Gaming (NASDAQ: SBET) achieving significant market cap growth as capital market highlights, Japan lacks a similar listed benchmark. Quantum Solutions’ entry fills this gap, opening a new chapter as "Japan’s first”, and creating conditions for capital inflow and renewed market participation.This financing round, nominally valued at approximately USD 180 million, is a landmark in both the Japanese stock market as well as the crypto-linked equities space. Through the combined endorsement of SIG, ARK, and IAM, Quantum not only secures funding but also international validation under a capital structure optimized to maximize long-term shareholder value. High-profile deals of this caliber further Tokyo as an emerging destination for savvy investors. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

東京，2025年9月29日 - (亞太商訊 via SeaPRwire.com) - 據Quantum Solutions Co.,Ltd.（東京證券交易所代碼：2338，下稱「Quantum Solutions」）於2025年9月26日發布的公告顯示，公司已啟動超260億日圓（約1.8億美元）的戰略融資計劃，首輪募集金額達221億日圓（約1.5億美元），公告列出三家國際機構資本參與。這一消息一經公布，隨即引發廣泛關注。觀察人士指出，對日本投資者而言，這是繼巴菲特入股五大商社後，多家美國機構資本對日本資本市場的又一次深度押注；對國際投資者而言，這則意味著日本市場正加速向全球創新資本開放，迎來全新價值重估機會。多家國際機構資本同台亮相，日本市場再獲國際加持本輪融資的投資者組合被部分市場人士稱為「國際資本夢幻陣容」。由Cathie Wood主導的ARK Invest首度將版圖拓展至亞洲，被市場視為其在美國之外的重要戰略突破。ARK長期以來以精準捕捉破壞式創新與新興科技趨勢聞名，市場人士認為，ARK的此次入局被解讀為對Quantum Solutions戰略定位的高度認可，也折射出國際創新資本對日本市場的積極態度。與此同時，全球最大量化交易與專業投資集團之一的SIG（Susquehanna International Group），據公開資料，透過旗下CVI Investments出手，其資本市場經驗與風控能力被認為可為Quantum Solutions後續的流動性管理與資本效率優化提供制度性支持。第三位參與者則是由任德章（TC Yam）先生領導的Integrated Asset Management（IAM）。IAM結合國際金融與媒體資源的跨界優勢，被部分觀察人士視為有助於Quantum Solutions增添資本實力，更進一步鞏固其在全球投資者社群中的聲譽與公信力。三家重量級機構的聯手進駐，無論從資金來源還是象徵意義上，被部分市場人士視為為Quantum Solutions及日本資本市場帶來強力背書。在融資架構上，本輪主要採用可轉換債券以及浮動與固定行權價認股權證，合計發行規模約4,400萬股，近似於現有股份的翻倍。市場分析認為，該融資架構顯示國際投資者對Quantum Solutions長期發展前景的信心，另一方面也為公司未來的戰略轉型提供了充足資本彈藥。市場分析人士指出，經過本次融資強化後，Quantum Solutions的資本結構更趨穩健，不僅具備更強的抗風險能力，亦為投資者帶來估值修復與長期增長的雙重空間。ETH Treasury首例登場，差異化戰略開啟新賽道此次融資落地後，Quantum Solutions將正式啟動其ETH Treasury戰略，以募集資金長期持有以太坊（ETH）。虽在公告内未提及具体运营计划，但市场预测，Quantum Solutions会在合規框架下透過Staking、智能合約與多元流動性策略實現資產增值與風險管理。至此，Quantum Solutions將成為日本首家实质性将ETH納入公司金庫（Treasury）的上市公司，開創本土市場的歷史先例。與眾多選擇比特幣（BTC）作為核心資產的公司不同，Quantum Solutions在戰略層面另闢蹊徑。ETH不僅是一種數位資產，更是整個區塊鏈應用層的基礎設施。其智能合約功能為去中心化金融（DeFi）、NFT、生態協議等提供支撐，使其具備更持續的增值潛力。美國市場的數據顯示，ETH Treasury的估值普遍高於BTC Treasury，市淨率溢價約為6.5倍，顯示投資者對ETH帶來的長期回報有更高期待。換言之，ETH Treasury的差異化邏輯在於「資產+應用」的雙重驅動，有分析認為，Quantum Solutions的策略恰恰抓住了這一先行者優勢。本輪融資完成後，预测其公司預計可逐步累積超過8萬枚ETH，並有望在短期內躋身全球領先的ETH Treasury公司之列。市場觀察認為，結合ARK、SIG與IAM的戰略協同，Quantum Solutions不僅能夠獲得資金與專業知識的輸入，還將在品牌、技術與合規治理方面持續受益。部這一戰略落地對日本市場而言，既是一次新資產類別的制度性突破，也將為本土上市公司在全球區塊鏈版圖中提供一個可供複製的成功範例。對於零售投資者來說，這意味著他們能夠首次通過傳統資本市場的管道，間接參與ETH相關收益，開啟全新的投資故事。日本政策紅利釋放，Quantum Solutions長期主義聚焦股東價值日本市場正在迎來新的轉折點。隨著政府在Web3政策上不斷釋放利好訊號，監管環境日漸清晰與友善，投資者正尋找新的參照標的。相比之下，美國已經出現了BitMine、BTCS等BTC/ETH Treasury公司，市值一路走高，成為資本市場的新焦點；而日本卻一直缺乏同類型的上市公司。分析人士認為，Quantum Solutions的進場，不僅填補了這個空白，更以「日本第一」的身份打開新的篇章。它的出現，等於在市場上立下一個新的定價參考，讓投資者有了一個全新故事可以跟隨，也為資金流入和市場活化創造了條件。值得注意的是，根據公開資訊，Quantum Solutions管理層多年來持續探索新賽道。他們曾經推動AI算力、雲端基礎設施和數位解決方案等業務轉型，每一步都在嘗試新的增長曲線。本輪超260億日圓的融資落地，更是一次關鍵轉折點。市場解讀認為，隨著ARK、SIG和IAM三大國際資本的聯手加持，公司不僅獲得資金支持，更得到國際市場的高度背書，釋放出「聚焦股東價值最大化」的明确信號。分析人士指出，投資者因此認為Quantum Solutions不僅有資本實力，還有國際資源與長期戰略，市場信心自然水漲船高。根據公開資訊，Quantum Solutions管理層一直在探索新賽道。从推動AI算力、雲端基礎設施和AIGC解決方案，每一步都在寻求新的增長曲線。本輪超260億日圓的融資落地，是一次關鍵轉折點。隨著ARK、SIG和IAM三大國際資本的聯手加持，公司不僅獲得了資金支持，更得到國際市場的背書，釋放出「聚焦股東價值最大化」的明确信號。關於 Quantum Solutions根據其官網與公開資訊，Quantum Solutions Co.,Ltd.（東京證券交易所：2338）是一家總部位於日本東京的高成長科技企業，專注於人工智能、大數據分析及區塊鏈相關技術的研發與應用。公司成立於2004年，並於東京證券交易所掛牌上市。更多信息請訪問公司官網：https://www.quantum-s.co.jp/en/corporate前瞻性聲明本新聞稿包含根據公司目前可取得之資訊，以及對未來事件與預期所作的若干假設所形成的前瞻性聲明。此類聲明涉及各種風險與不確定性，包括但不限於政策變動、市場狀況、技術發展及監管因素，皆可能導致實際結果與此類聲明中所表達或暗示的結果出現重大差異。建議現有及潛在投資者審慎評估潛在風險，並避免對本新聞稿中所包含的任何前瞻性聲明寄予過高信賴。此類聲明僅適用於本新聞稿發佈之日，除法律另有規定外，公司並無義務因新資訊、未來事件或其他情況而更新或修正任何前瞻性聲明。如有進一步查詢，請聯絡：香港/國際：Mr. Steven TungEmail: publicrelations@quantum-s.co.jp日本：Ms. Linda PengEmail: publicrelations@quantum-s.co.jp Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAIPEI, TAIWAN, 2025年9月29日 - (亞太商訊 via SeaPRwire.com) - 新加坡 —— 新交所凱利板上市公司 Mooreast Holdings Ltd.（以下簡稱「Mooreast」或「集團」）今日表示，已與中國交通建設股份有限公司（「中交股份」）旗下子公司簽署《戰略合作協議》（「SCA」）。中交股份是中國國有的全球基礎設施開發領導企業。根據該協議，Mooreast 與中交機電工程有限公司（「中交機電」）計劃合作，在中國及全球其他地區共同開發浮式海上再生能源及相關近海與海洋工程專案的商機。該戰略合作將充分發揮中交機電在中國境內的規模化營運、專業技術、資源、聲譽與網絡優勢，同時結合Mooreast 在綠色低碳發展與浮式再生能源領域（包括海上風電）的技術能力、成功經驗與國際網絡。雙方亦將探索建立海上風電相關產業供應鏈的合作機會，提供涵蓋工程、採購、施工與安裝（EPCI）的綜合解決方案。Mooreast 與中交機電計劃推進涉及浮式風能及其他近海與海洋工程專案的合作，範圍包括工程設計、生產、分裝、運輸及／或系泊與索具系統、風力發電機、浮式平台及相關零部件或設備的安裝等。儘管這些產品與解決方案的主要市場在中國本土，但鑑於亞洲地區技術水平日益提升且生產成本持續下降，雙方亦看好海外市場的成長機遇。作為近海與海洋領域系泊與索具系統的專業公司，Mooreast 是亞洲唯一一家超高功率錨具設計與製造商。隨著全球浮式風電專案的商業化步伐加快，公司正積極擴展其在歐洲和東北亞的市場布局。Mooreast 執行董事兼副主席沈君南先生表示：「我們非常高興並榮幸能與中交機電這樣享有盛譽的企業建立合作。與陸上風電相比，中國的浮式海上風電產業仍有巨大潛力尚待開發。我們期待在不久的將來深化合作，把握國內外市場機遇。」本新聞稿已由公司贊助商大華繼顯私人有限公司（「贊助商」）審閱。本新聞稿尚未經新加坡交易所有限公司（「SGX-ST」）檢驗或批准，SGX-ST 對本新聞稿的內容不承擔任何責任，包括其中所載之陳述、意見或報告的正確性。贊助商聯絡人為大華繼顯私人有限公司高級副總裁 Lance Tan先生，地址：83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920，電話：(65) 6590 6881。本新聞稿由 WeR1 Consultants Pte Ltd 代表 Mooreast Holdings Ltd. 發佈。關於 Mooreast Holdings Ltd.作為全面系泊解決方案的領導者，Mooreast 為近海石油與天然氣、航運及海上再生能源產業提供系泊系統的設計、工程、製造、供應與物流、安裝及調試等服務。憑藉近三十年的經驗，Mooreast 正將其在系泊解決方案領域的實績與專業能力應用於浮式再生能源專案，特別是浮式海上風電。公司已成功參與日本與歐洲的浮式海上風力發電機開發與原型專案。更多資訊，請瀏覽 https://mooreast.com/媒體與投資者聯絡方式WeR1 Consultants Pte LtdIsaac Tang, mooreast@wer1.net（手機：+65 9748 0688） Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com